<DOC>
	<DOCNO>NCT01459159</DOCNO>
	<brief_summary>This multicenter , single arm open label Phase 2b Study oral ezatiostat ( Telintra® ) Patients RBC tranfusion dependent , Low INT-1 IPSS risk , non-del ( 5q ) Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>Study ( Telintra® ) Non-Del ( 5q ) Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Primary de Novo MDS Low Intermediate1 IPSS risk MDS ECOG performance score 0 1 Documentation significant anemia without additional cytopenia Adequate kidney liver function Patients must discontinue hematopoietic growth factor least 3 week prior study entry Deletion 5q chromosome [ del ( 5q ) MDS ] Prior allogenic bone marrow transplant MDS Known sensitivity ezatiostat ( injection oral tablet ) Prior treatment hypomethylating agent ( HMA ) ( e.g. , azacitadine , decitabine ) History MDS IPSS risk score great 1.0 Pregnant lactate woman Any severe concurrent disease , infection comorbidity , judgement investigator , would make patient inappropriate study entry Oral steroid great 10 mg per day . Exceptions : prescribe condition ( new adrenal failure , asthma , arthritis ) brief sterioid use ( tapered dose acute nonMDS condition ) History hepatitis B C , HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hematology</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Low risk MDS</keyword>
	<keyword>Int-1 risk MDS</keyword>
	<keyword>Transfusion dependence</keyword>
	<keyword>Telintra</keyword>
	<keyword>ezatiostat</keyword>
	<keyword>ezatiostat hydrochloride</keyword>
	<keyword>TLK199</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analog</keyword>
	<keyword>Glutathione Transferase</keyword>
	<keyword>Glutathione Transferase P1-1 inhibitor</keyword>
	<keyword>GST P1-1 inhibitor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Enzyme inhibitor</keyword>
	<keyword>non-del ( 5q )</keyword>
	<keyword>non-deletion 5q</keyword>
</DOC>